Jorge Ibanez-Vega
Overview
Explore the profile of Jorge Ibanez-Vega including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zoine J, Immadisetty K, Ibanez-Vega J, Moore S, Nevitt C, Thanekar U, et al.
Cell Rep Med
. 2024 Feb;
5(2):101422.
PMID: 38350450
The emergence of immune escape is a significant roadblock to developing effective chimeric antigen receptor (CAR) T cell therapies against hematological malignancies, including acute myeloid leukemia (AML). Here, we demonstrate...
2.
Haydar D, Ibanez-Vega J, Crawford J, Chou C, Guy C, Meehl M, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2430-2446.
PMID: 37971169
Significance: CAR T-cell immunotherapies hold great potential for treating brain cancers; however, they are hindered by a challenging immune environment that dampens their effectiveness. In this study, we show that...
3.
Tichauer J, Arellano G, Acuna E, Gonzalez L, Kannaiyan N, Murgas P, et al.
Front Immunol
. 2023 Jun;
14:1191838.
PMID: 37334380
Compelling evidence has shown that interferon (IFN)-γ has dual effects in multiple sclerosis and in its animal model of experimental autoimmune encephalomyelitis (EAE), with results supporting both a pathogenic and...
4.
Haydar D, Ibanez-Vega J, Crawford J, Chou C, Guy C, Meehl M, et al.
Res Sq
. 2023 Jun;
PMID: 37333156
Understanding interactions between adoptively transferred immune cells and the tumor immune microenvironment (TIME) is critical for developing successful T-cell based immunotherapies. Here we investigated the impact of the TIME and...
5.
Chockley P, Ibanez-Vega J, Krenciute G, Talbot L, Gottschalk S
Nat Biotechnol
. 2023 Feb;
41(10):1434-1445.
PMID: 36732477
Chimeric antigen receptor (CAR) technologies have been clinically implemented for the treatment of hematological malignancies; however, solid tumors remain resilient to CAR therapeutics. Natural killer (NK) cells may provide an...
6.
Carnevale J, Shifrut E, Kale N, Nyberg W, Blaeschke F, Chen Y, et al.
Nature
. 2022 Aug;
609(7925):174-182.
PMID: 36002574
The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints. Targeted gene editing has the potential...
7.
Haydar D, Ibanez-Vega J, Krenciute G
Front Oncol
. 2021 Nov;
11:718030.
PMID: 34760690
Despite decades of research, pediatric central nervous system (CNS) tumors remain the most debilitating, difficult to treat, and deadliest cancers. Current therapies, including radiation, chemotherapy, and/or surgery, are unable to...
8.
Ibanez-Vega J, Vilchez C, Jimenez K, Guevara C, Burgos P, Naves R
J Autoimmun
. 2021 Jul;
123:102702.
PMID: 34311143
Programmed Cell Death 1 (PD-1) receptor and its ligands (PD-Ls) are essential to maintain peripheral immune tolerance and to avoid tissue damage. Consequently, altered gene or protein expression of this...
9.
Ibanez-Vega J, Del Valle F, Saez J, Guzman F, Diaz J, Soza A, et al.
Front Cell Dev Biol
. 2021 May;
9:650817.
PMID: 34055780
The formation of an immune synapse (IS) enables B cells to capture membrane-tethered antigens, where cortical actin cytoskeleton remodeling regulates cell spreading and depletion of F-actin at the centrosome promotes...
10.
Ibanez-Vega J, Fuentes D, Lagos J, Cancino J, Yuseff M
J Vis Exp
. 2019 Jun;
(148).
PMID: 31205311
Recognition of surface-tethered antigens by the B cell receptor (BCR) triggers the formation of an immune synapse (IS), where both signaling and antigen uptake are coordinated. IS formation involves dynamic...